NYSE · Healthcare · Drug Manufacturers - General · USA
Bristol-Myers Squibb Co is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - General industry.
Bristol-Myers Squibb discovers, develops and sells innovative medicines addressing serious diseases including oncology, hematology, immunology and cardiovascular conditions. Its products span biologics, small molecule drugs and CAR-T cell therapies, distributed globally to wholesalers, pharmacies, hospitals and government agencies. The company maintains manufacturing operations across multiple countries including the United States, Puerto Rico, the Netherlands, Ireland and Switzerland.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Bristol-Myers Squibb Co stock.
Undervalued: intrinsic value $122.68 per share, market price $58.83, margin of safety 52.0% (as of 2026-10-19).
Discounting its cash flows at 6.7% (average of 3 methods) values the shares at $122.68; the price of $58.83 is 52% below that value, and 84% of that value comes from beyond year five.
Leak Score: 82/100 on 11 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
All 21 Drug Manufacturers - General stocks
BMY is undervalued (as of the 2026-10-19 close). Discounting its cash flows at 6.7% (average of 3 methods) values the shares at $122.68; the price of $58.83 is 52% below that value, and 84% of that value comes from beyond year five.
$122.68 per share (as of the 2026-10-19 close), against a market price of $58.83. That is a margin of safety of 52.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for less growth than the company has already delivered. Repeating its past would be enough. Yearly sales decline the price allows: 12.5%. Yearly sales decline it has shown: 0.2%.
82 out of 100, which we rate "Strong Leak", on 11 of 12 value investing signals.